Karen Smith, MD, PhD, MBA, LLM, joins with over 25 years of global pharma and biotech experience, having contributed to more than 20 regulatory approvals Dr Smith's appointment will accelerate Step Pharma's ‘pipeline in a product’ strategy, leveraging her clinical and regulatory expertise to advance dencatistat, afirst-in-class CTPS1 inhibitor across multiple cancer and blood disorder indicationsAppointment follows Step Pharma’s recently announced €38 million Series C financing Saint-Genis-Pouilly, France, ...

Core Insights - Context Therapeutics Inc. is set to present two posters at the Society for Immunotherapy of Cancer's 40th Annual Meeting, focusing on their T cell engaging bispecific antibodies for solid tumors [1][2] Presentation Details - The first poster will detail a Phase 1 clinical trial of CT-95, a mesothelin x CD3 TCE, scheduled for presentation on November 8, 2025 [3] - The second poster will present preclinical data on CT-202, a Nectin-4 x CD3 TCE, to be showcased on November 7, 2025 [3] Product Information - CT-95 targets mesothelin, a protein overexpressed in approximately 30% of cancers, and aims to minimize the impact of shed MSLN that can interfere with treatment [4] - CT-202 targets Nectin-4, which is overexpressed in various solid tumors, and is designed to be preferentially active in the tumor microenvironment [5] Company Overview - Context Therapeutics is focused on developing T cell engaging bispecific antibodies, including CTIM-76, CT-95, and CT-202, and is headquartered in Philadelphia [6]

PHILADELPHIA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced two posters will be presented at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting, being held November 7–9, 2025, at the Gaylord National Resort and Convention Center in National Harbor, MD. Context’s poster presentations will include a Tri ...

PHILADELPHIA, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted non-qualified stock option awards to purchase 30,000 shares of its common stock to a new employee as an inducement material for accepting employment with Context. The stock option awards were granted outside of the Context Therapeutics Inc. 20 ...

Core Insights - Context Therapeutics Inc. is advancing its clinical pipeline with two bispecific antibodies, CTIM-76 and CT-95, and expects to share initial dose escalation data in 2026 [2][3] - The company reported cash and cash equivalents of $83.5 million as of June 30, 2025, which is projected to fund operations into 2027 [1][10] - The net loss for the second quarter of 2025 was $8.8 million, compared to a loss of $2.3 million in the same period of 2024 [6][9] Pipeline Updates - CTIM-76 is a selective Claudin 6 x CD3 bispecific antibody, while CT-95 is an avidity enhanced mesothelin x CD3 bispecific antibody [2][7] - The company plans to initiate a first-in-human trial for CT-202, a Nectin-4 x CD3 bispecific antibody, in the second quarter of 2026 [2] Financial Performance - Research and development expenses for Q2 2025 were $7.8 million, significantly higher than $1.4 million in Q2 2024, driven by increased costs associated with CT-202, CT-95, and CTIM-76 [5][9] - General and administrative expenses rose to $1.9 million in Q2 2025 from $1.7 million in Q2 2024, primarily due to higher personnel-related costs [5][9] - Other income for Q2 2025 was approximately $0.9 million, slightly up from $0.8 million in Q2 2024, mainly due to increased interest income [5][9] Corporate Updates - The company appointed Dr. Karen Chagin as Chief Medical Officer in June 2025 [5] - Context Therapeutics presented at several conferences, including the ASCO Annual Meeting and the AACR Annual Meeting in 2025 [5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ______________. Commission file number: 001-40654 CONTEXT THERAPEUTICS INC. (Exact name of registrant as specified in its charter) ________________ ...

Group 1 - Ms. Fiakas has extensive experience in investment banking and research analysis, focusing on equity capital markets, particularly in emerging growth companies within technology, energy, and conservation sectors [1] - Ms. Fiakas is the Managing Member of Crystal Equity Research, LLC, which specializes in analyzing small-cap companies [1] - The article emphasizes the importance of understanding the dynamics of emerging growth companies for potential investment opportunities [1] Group 2 - Crystal Equity Research does not have a beneficial interest in the companies mentioned, ensuring an unbiased analysis [2] - The Prime series underwriters may have a beneficial interest in the companies discussed, indicating potential conflicts of interest [2]

Core Insights - Context Therapeutics Inc. is advancing CTIM-76, a Claudin 6 x CD3 T cell engager, in a Phase 1 clinical trial targeting ovarian, endometrial, and testicular cancers, with initial data expected in the first half of 2026 [1][7]. Group 1: Clinical Trial Details - The Phase 1 trial is an open-label, dose escalation and expansion study aimed at evaluating the safety and efficacy of CTIM-76 in patients with CLDN6-positive advanced or metastatic cancers [2]. - The trial plans to enroll up to 70 patients and will assess safety, tolerability, pharmacokinetics, and anti-tumor activity through various metrics [2]. Group 2: Presentation Information - A poster presentation titled "A phase 1, first-in-human study of CTIM-76" will be showcased at the 2025 ASCO Annual Meeting on June 2, 2025 [3]. - The presentation will be available on the company's website under the "Publications and Posters" section [3]. Group 3: Product Overview - CTIM-76 is a bispecific antibody that targets CLDN6, which is prevalent in various solid tumors, including ovarian and endometrial cancers [4]. - Preclinical studies indicate that CTIM-76 may offer convenient dosing with low immunogenicity risk and scalable manufacturing capabilities [4]. Group 4: Company Background - Context Therapeutics Inc. is focused on developing T cell engaging bispecific antibodies for solid tumors, with a portfolio that includes CTIM-76, CT-95, and CT-202 [5]. - The company is headquartered in Philadelphia and actively engages with the investment community through various channels [5].

Core Insights - Context Therapeutics Inc. has appointed Dr. Karen Chagin as Chief Medical Officer, effective June 9, 2025, succeeding Dr. Karen Smith who will remain on the Board of Directors [1][4] - Dr. Chagin has over a decade of experience in clinical development and regulatory strategy for T cell therapies, having previously held senior roles at Adaptimmune and Tmunity [2][3] - The company is focused on advancing T cell engaging bispecific antibodies for solid tumors, with a portfolio that includes CTIM-76, CT-95, and CT-202 [7] Leadership Transition - Dr. Chagin's appointment is seen as pivotal for the company's growth, bringing valuable insights from her experience in moving programs from early development to approval [4] - Dr. Smith's interim leadership has been acknowledged, highlighting her contributions during the transition [4] Stock Option Grant - As part of her employment, Dr. Chagin will receive a non-qualified stock option award of 153,000 shares, with the exercise price based on the closing price of the company's stock on her start date [5][6] - The stock option will vest over four years, with 25% vesting on the first anniversary and the remainder in equal monthly installments [6] Company Overview - Context Therapeutics is a biopharmaceutical company headquartered in Philadelphia, specializing in T cell engaging bispecific antibodies for solid tumors [7]

Core Insights - Context Therapeutics Inc. is advancing its clinical pipeline with two product candidates, CTIM-76 and CT-95, currently in Phase 1 clinical trials, with initial clinical data expected in 2026 [2][3] - The company reported cash and cash equivalents of $89.4 million as of March 31, 2025, which is projected to fund operations into 2027 [2][10] - Research and development expenses increased to $3.5 million in Q1 2025 from $2.0 million in Q1 2024, primarily due to costs associated with CT-202 and CT-95 [5][9] Financial Performance - For the first quarter of 2025, Context reported a net loss of $4.6 million, compared to a loss of $3.7 million in the same period of 2024 [6][9] - General and administrative expenses rose to $2.1 million in Q1 2025 from $1.9 million in Q1 2024, driven by increased personnel costs [5][9] - Other income for Q1 2025 was approximately $1.0 million, up from $0.2 million in Q1 2024, mainly due to higher interest income [5][9] Upcoming Developments - The company plans to file an Investigational New Drug (IND) application for CT-202, a potential best-in-class Nectin-4 x CD3 bispecific antibody, in mid-2026 [2][3] - Context will present at the Citizens Life Sciences Conference on May 8, 2025, and participate in one-on-one meetings at the D. Boral Capital Inaugural Global Conference on May 14, 2025 [5][4]